Meanwhile, the BSE Sensex was down 11.82 points or 0.06% at 19,464.18.
On BSE, 13,000 shares were traded in the counter as against average daily volume of 13,481 shares in the past one quarter.
The stock hit a high of Rs 505.20 so far during the day, which is a record high for the counter. The stock hit a low of Rs 494.35 so far during the day. The stock had hit a 52-week low of Rs 223.50 on 20 December 2011.
The stock had outperformed the market over the past one month till 19 December 2012, surging 21.26% compared with the Sensex's 6.2% rise. The scrip had also outperformed the market in past one quarter, jumping 28.96% as against Sensex's 5.3% gain.
The company has equity capital of Rs 31.37 crore. Face value per share is Rs 10.
Shares of Natco Pharma have surged 7.28% in two trading sessions from Rs 467.40 on 18 December 2012, after the company during trading hours on Wednesday, 19 December 2012 said it has received the approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lansoprazole Delayed Release Capsules, USP, 15 milligrams (mg), and 30 mg, for the prescription market. The stock had surged 4.88% to settle at Rs 490.25 on Wednesday, 19 December 2012.
Natco Pharma said that shipments of Lansoprazole Delayed Release Capsules, USP, 15 mg and 30 mg will commence immediately.
Natco Pharma's consolidated net profit jumped 31.7% to Rs 20.99 crore on 37.9% growth in net sales to Rs 171.83 crore in Q2 September 2012 over Q2 September 2011.
Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.
Powered by Capital Market - Live News
